ABVCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ECOC
ABVC BIOPHARMA, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.91−0.01 (-0.86%)
Close on Oct 19, 2026
- Market cap
- $23.71M
- P/E (TTM)
- –
- Dividend yield
- –
ABVC BIOPHARMA, INC. revenue by segment
By business segment
By product or service
| Revenue | Q1 26 | Q4 25 | Q3 24 | Q3 23 | % of revenue |
|---|---|---|---|---|---|
| Other revenues | – | – | $9.28K | $15.88K | – |
| Licensing revenues | – | – | $380.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Abvc Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.